Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different.
Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as COVID revenue fades and generic and biosimilar competition pressures parts of its older portfolio.
DON’T MISS: Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?
Their latest results suggest both stories are improving, but the more important question for investors is which turnaround has the stronger foundation. Let’s take a deeper look.
Bull Case
Thermo Fisher currently has the clearer operating momentum, as its second-quarter revenue increased 10% to $11.99 billion, including 5% organic growth, while adjusted EPS rose 13% to $6.03. Adjusted operating margin also expanded to 22.8% from 21.9% a year earlier. The recovery was broad enough for management to highlight strengthening customer activity across its end markets. Life Sciences Solutions revenue increased 13% on a reported basis and 3% organically, helped by bioproduction, while Analytical Instruments returned to growth after a difficult period. Thermo Fisher subsequently raised its full-year adjusted EPS outlook to $24.93-$25.33.
Pfizer’s turnaround is less advanced, but there are signs that the business underneath COVID is gaining traction. Second-quarter revenue increased 3% to $15.03 billion, while revenue excluding Comirnaty and Paxlovid grew 5% operationally. Its group of recently launched and acquired products grew 18% operationally.
READ NEXT: Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
Several individual medicines also contributed, with Padcev growing 23% operationally, the Vyndaqel family growing 8%, and Lorbrena increasing 37%. Better-than-expected non-COVID performance also allowed Pfizer to raise the midpoint of its 2026 revenue guidance by $500 million to $61.5 billion, even as it reduced expected COVID-product revenue from approximately $5 billion to approximately $4 billion.
Pfizer also has a major cost lever, as the company expects approximately $6.7 billion in total net savings from its cost-realignment program through 2029 and another $3 billion from its manufacturing-optimization program. Those are company targets rather than savings already realized, but successful execution could create a leaner cost base as newer products scale.
Bear Case
Thermo Fisher’s (NYSE:TMO) biggest risk is that investors begin treating an improving life-sciences market as a completed recovery. Its 5% organic growth was encouraging, and customer activity improved, but parts of the market are still stabilizing. If pharmaceutical and biotech customers pull back spending again, the recovery in instruments and other research-related businesses could lose momentum.
Pfizer faces a more structural challenge. While total fiscal Q2 revenue increased 3%, operational growth was only 1%, with foreign exchange contributing $217 million to the reported increase. Pfizer also recorded a $248 million GAAP net loss after $4.3 billion of non-cash intangible-asset impairments. More importantly, the company still has to prove that its newer portfolio can grow quickly enough to offset future losses of exclusivity. Its 2026 guidance already assumes an approximately $1.1 billion unfavorable revenue impact from recent and expected generic and biosimilar competition. Cost reductions can support earnings, but they cannot by themselves replace revenue lost when established medicines face competition.
Conclusion
The comparison comes down to what investors want from a turnaround. Pfizer potentially offers a more dramatic transformation if its newer medicines continue growing, its pipeline delivers, and management realizes its planned cost savings. But more pieces still need to fall into place, particularly as loss-of-exclusivity pressure builds.
Thermo Fisher’s (NYSE:TMO) recovery is already showing up more clearly in the numbers, and can be corroborated by the 5% organic growth, expanding adjusted margins, double-digit adjusted EPS growth, and stronger customer activity.
That makes Thermo Fisher the more operationally advanced turnaround today, while Pfizer remains the higher-execution-risk story. Investors looking for evidence that a recovery is already taking hold may therefore find TMO’s current trajectory easier to underwrite, as Pfizer’s case depends more heavily on what its newer portfolio and pipeline can deliver over the next several years.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
